Novartis is a global healthcare company based in Switzerland that is dedicated to addressing the evolving needs of patients worldwide. With a focus on neuroscience, Novartis has recently acquired Cadent Therapeutics, a neuroscience company based in Cambridge, Massachusetts. This acquisition adds two new clinical stage programs to Novartis' neuroscience portfolio, specifically for schizophrenia and movement disorders.

Additionally, Novartis has secured the rights to MIJ821, a clinical stage molecule that it licensed exclusively from Cadent in 2015. MIJ821 is currently being developed by Novartis to address treatment-resistant depression. With this latest agreement, Novartis is reaffirming its commitment to developing innovative solutions in the field of neuropsychiatric disorders.

With its expertise in neuroscience, Novartis continues to provide cutting-edge products and services to improve the lives of patients worldwide